{"nctId":"NCT00713310","briefTitle":"Assessing the Safety/Efficacy of AsacolÂ® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis","startDateStruct":{"date":"2008-12"},"conditions":["Ulcerative Colitis"],"count":83,"armGroups":[{"label":"Low-Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Asacol 400 mg"]},{"label":"High-Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Asacol 400 mg"]}],"interventions":[{"name":"Asacol 400 mg","otherNames":[]},{"name":"Asacol 400 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* are male or female between the ages of 5 and 17 years, inclusive, at the time of the first dose of study medication, with a history of biopsy and endoscopy confirmed UC;\n* have mildly-to-moderately active UC (either newly diagnosed or that has relapsed) as defined clinically by a Pediatric UC Activity Index (PUCAI) score 10 and 55, and, in the opinion of the Investigator, the patient does not require steroids;\n* have baseline scores of at least 1 for both rectal bleeding (Streaks of blood with stool less than half of the time) and stool frequency (1-2 stools greater than normal per day) as defined by the TM-Mayo Score\n\nExclusion Criteria:\n\n* have UC known to be confined to the rectum (isolated rectal proctitis);\n* have a history of allergy or hypersensitivity to salicylates, aminosalicylates, or any component of the Asacol tablet;\n* have a significant co-existing illness or other condition(s), including but not limited to cancer or significant organic or psychiatric disease on medical history or physical examination, that, in the judgment of the Investigator, contraindicate(s) administration of the study drug and/or any study procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population","description":"PUCAI 0-85, abdominal pain (no pain/0, pain ignored/5, pain not ignored/10), rectal bleeding (none/0, small \\<50% stool/10, small with most stools/20, large \\>50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, \\>8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission \\<10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score\\<10 at Wk 6 (complete) or reduction of \\>=20 points baseline to Wk 6 with Wk 6 score\\>=10 (partial)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT","description":"PUCAI 0-85, abdominal pain amended (no pain/0, very mild/2.5, mild/5, moderate/7.5, severe/10), rectal bleeding (none/0, small \\<50% stool/10, small with most stools/20, large \\>50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, \\>8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission \\<10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score\\<10 at Wk 6 (complete) or reduction of \\>=20 points baseline to Wk 6 with Wk 6 score\\>=10 (partial)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"57.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":41},"commonTop":["Nasopharyngitis","Colitis Ulcerative","Headache","Fatigue","Dizziness"]}}}